Bill Curry, a 65-year-old cattle farmer in rural Oklahoma, used to drive two and a half hours to Oklahoma City every few months for an epidural injection in his spine. This year, because of Medicare’s new AI-driven prior-authorization program, he had to make the drive three times — once for an unexpected preapproval appointment, once for the injection, and a third time for paperwork his clinic had never required before. He skipped the third trip.
Curry’s experience is not isolated. The KFF Health News investigation documents systematic delays, errors, and patient harm across the six pilot states where CMS launched the Wasteful and Inappropriate Service Reduction Model — WISeR — in January 2026.
🔍 THE BOTTOM LINE: Medicare deployed AI to catch fraudulent or unnecessary procedures, but the program produced automated denials with inadequate clinical oversight and weak appeal pathways. A federal reprimand followed. The Senate voted to keep it running anyway.
How WISeR Works
CMS launched WISeR on January 1, 2026, in Arizona, Ohio, Oklahoma, Texas, Washington, and New Jersey. The program requires prior authorization for 13 medical services the Trump administration identified as prone to fraud or misuse — epidurals, kyphoplasty, skin substitutes, and others. Doctors submit clinical records through online portals. AI systems review the submissions and approve or deny.
Vendor Humata Health, which runs Oklahoma’s program, says 88 per cent of applications with supporting clinical data receive an “immediate yes.” CMS has touted 72-hour decision turnaround. In practice, participants describe six-to-eight-week delays, denied claims for procedures that met criteria, and denials citing medical conditions the patient did not have.
Oklahoma radiologist James Webb documented four times that a patient lacked numbness — a condition that would rule out a kyphoplasty — and yet the WISeR application was still denied, citing numbness. Jerry Sobel, a Phoenix pain management doctor, told KFF Health News he had not been paid by Medicare for nine epidurals as of May. “It’s been horrendous,” he said. “Right from the beginning, there seemed to be no organization.”
The Federal Reprimand
The AI Failure Index reported a federal reprimand arising from the WISeR pilot, citing three interlocking failures: insufficient clinical oversight of automated authorization decisions, inadequate appeal pathways for affected beneficiaries, and weak validation of model outputs before they affected access to care.
Separately, CMS required Virtix Health — the Arizona vendor — to submit a corrective action plan after the company failed to meet the 72-hour turnaround requirement, according to DistilINFO. CMS is now holding biweekly meetings with Virtix to track progress.
The AI Governance Institute describes the reprimand as a concrete enforcement precedent: healthcare organisations using AI in prior authorization or utilisation management now have a federal action to cite in risk assessments. Deploying automated denial systems without documented human override protocols and validated model outputs is no longer a theoretical liability.
The Payment Structure Problem
Virtix is compensated based on a share of averted Medicare expenditures. That means the vendor has a financial stake in denials. This is not a accusation of wrongdoing — performance-based contracts are standard in government outsourcing. But the structure raises a question: does a vendor that profits from denials have sufficient incentive to ensure those denials are correct?
CMS said processing times have improved from an average of five days in the first four months to 1.7 days for prior authorization and just over three days for prepayment review. But speed of denial is not the same as accuracy of denial. The federal reprimand focused on clinical oversight and appeal pathways, not just turnaround time.
Congress Tried to Stop It. The Senate Said No.
The House Appropriations Committee moved an amendment on June 9 to block federal funding for WISeR. More than two dozen House lawmakers sent a letter to CMS Administrator Mehmet Oz requesting data on appeals and denials during the program’s first six months. On July 16, STAT News reported that Senate Republicans blocked an effort to end the pilot, keeping it alive through its scheduled 2031 conclusion.
The political split is stark. Democrats framed the vote as protecting seniors from automated care denials. Republicans framed it as preserving a fraud-reduction tool. Neither side addressed the core governance question: whether AI-driven benefit decisions should require independent clinical review before they take effect, not after a patient files an appeal.
What NZ Should Note
New Zealand’s health system does not have a prior-authorization mechanism comparable to WISeR. But Te Whatu Ora has been exploring AI for clinical decision support, and the Health Information Standards Organisation has published guidance on algorithmic accountability in healthcare. The WISeR case offers a cautionary template: deploying AI in consequential healthcare decisions without validated model outputs, independent clinical review, and robust appeal pathways led to documented patient harm and federal enforcement action. NZ’s relatively centralised health system could move faster on governance controls than the fragmented US system — or it could repeat the same mistakes.
❓ FAQ
What is prior authorization? Prior authorization requires doctors to get insurance approval before performing certain procedures, tests, or prescriptions. It has been standard in private US insurance for years. Medicare traditionally avoided it. WISeR introduced it to traditional Medicare for 13 specific services.
Why did CMS launch WISeR? The Department of Health and Human Services inspector general warned that spending on certain services — skin substitutes, for example — had surged nearly 700 per cent over two years, raising concerns about fraud, waste, and abuse. WISeR uses AI to review whether specific procedures are medically necessary before approving payment.
Are AI systems making the final denial decisions? CMS vendors say humans make the final call. Doctors and clinic staff involved in the pilot say AI is clearly playing a large role, and that denials sometimes appear to result from AI errors — including a denial citing numbness in a patient who did not have numbness. The federal reprimand cited insufficient clinical oversight, which suggests the human review layer may not be functioning as described.
Is the WISeR program still running? Yes. The Senate voted on July 16 to keep it in place. The program is scheduled to run through December 31, 2031. CMS said it has “currently no changes” planned for the list of services subject to review, but continues to “assess whether any changes are warranted.”
📰 Sources
- KFF Health News — Medicare’s AI Push Snarls Patients and Doctors in Errors and Delays
- AI Governance Institute — Federal Reprimand Over Medicare AI Prior-Auth
- STAT News — GOP blocks effort to end Medicare test of AI prior authorization
- DistilINFO — CMS Reprimands AI Vendor Over WISeR Prior Authorization Delays
- CMS — WISeR Model page
